Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2879400 | 1.00 | NR1H2 (0.42) | NR1H2SMN1; SMN2HRH3GPR119USP30 | |
| SCHEMBL2884982 | 0.82 | LIPE (0.42) | NR1H2HRH3GPR119PDE4B | |
| SCHEMBL30890364 | 0.73 | NR1H2 (0.46) | NR1H2SMN1; SMN2HRH3GPR119USP30 | |
| SCHEMBL15785400 | 0.73 | GPR119 (0.49) | NR1H2SMN1; SMN2GPR119USP30HDAC1 | |
| SCHEMBL31485228 | 0.73 | JAK1 (0.48) | NR1H2HRH3GPR119USP30HDAC1 | |
| SCHEMBL23783164 | 0.73 | GPR119 (0.58) | NR1H2SMN1; SMN2GPR119 | |
| SCHEMBL19211006 | 0.73 | JAK1 (0.48) | NR1H2HRH3GPR119USP30HDAC1 | |
| SCHEMBL29577114 | 0.73 | JAK1 (0.48) | NR1H2HRH3GPR119USP30HDAC1 | |
| SCHEMBL660403 | 0.73 | NR1H2 (0.53) | NR1H2SMN1; SMN2GPR119 | |
| SCHEMBL29508938 | 0.73 | NR1H2 (0.53) | NR1H2SMN1; SMN2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828991-B2 | Azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments | SANOFI (FR) | 2014-09-09 | — | — | US | disclosed |
| US-20090082339-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082339-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | MCHR1, MPI, TPMT | NR1H2 2498/4885SMN1; SMN2 3618/4885HRH3 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.